Podcasts about Medtronic

In this wide-ranging and direct conversation, Bill George, former Medtronic CEO and Harvard Business School professor, offers a disciplined framework for leading in conditions of persistent volatility. Drawing from decades of leadership experience and research, George emphasizes that leadership today is no longer about managing processes, it is about confronting ambiguity, enabling experimentation, and sustaining purpose across shifting conditions.   Five themes stand out: Opportunity Must Be Created, Not Awaited. George argues that emerging leaders should not wait for promotions or formal permission. Instead, they should identify unaddressed problems, volunteer to lead, and deliver results without demanding titles. Career growth, he suggests, is a function of action, not seniority. Innovation Begins at the Front Lines. Whether referencing his early decision to cancel a Medtronic pacemaker program that lacked patient benefit, or urging leaders to spend less time in conference rooms and more with customers and staff, George insists that enduring breakthroughs stem from direct observation and empathy, not from internal data analysis alone. Risk Tolerance Determines Strategic Renewal. George contrasts firms that institutionalize risk such as Medtronic's venture incubation model, with those that allow internal resistance to block change. Innovation, he asserts, must be structurally protected from corporate inertia, and leaders should be judged on the courage to champion unpopular ideas that later prove transformative. Culture Must Reward Learning Over Defensiveness. Drawing parallels between U.S., European, and Japanese innovation cultures, George critiques over-regulated, failure-averse systems that suppress experimentation. True progress, he says, requires the willingness to learn through trial, adaptation, and even initial failure. AI Is a Strategic Imperative, Not a Cost Play. Rather than using AI to drive out labor costs, George advocates for using it to rethink business models entirely, supporting frontline autonomy, enabling new services, and unlocking unmet needs. He cautions leaders against adopting a defensive posture and urges them to fund experiments that explore the true potential of the technology. Throughout, George offers a leadership mindset anchored in authenticity, courage, and customer-centric design. His advice is clear: future leaders must raise their hands, operate at the edge, and move fast before the window of relevance closes.   Get Bill's book here: https://shorturl.at/3iHRb True North, Emerging Leader Edition: Leading Authentically in Today's Workplace   Here are some free gifts for you:   Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach   McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf   Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo  

生醫工程是近年來熱門的專業，由於生醫工程是一個較新的專業，很多人對於生醫工程的職涯和出路並不熟悉。 這一集我們特別邀請到目前在腦機介面領頭羊公司 Synchron 擔任 Principal System Engineer 的張耀銓博士和我們分享他一路以來的職涯：如何從電機/電控學士轉到生醫工程博班，從學界如何透過與業界密切合作的機構進入業界、如何進到醫療器材大廠 Medtronic 和現在的 Synchron，以及在學習和求職上遇到各種挑戰與心得。 張耀銓博士也在上一集中，和我們分享了侵入式腦機介面目前的進展和 Synchron 的獨特優勢，對腦機介面發展有興趣的朋友歡迎到上一集收聽。  

HealthLeaders' Michelle Ponte sits down with Rob St. John, senior clinical director and technical fellow for the Acute Care and Monitoring Division of Medtronic, to learn how HealthCast's portfolio can allow nurses and clinicians to deliver better care without replacing them.

Ce vendredi 13 juin 2025,Christian Bito, professeur de finance à l'ESSEC Business School, et Frédéric Rozier, gérant chez Mirabaud France, se sont penchés sur les titres Leonardo DRS et Medtronic, dans On achète ou on vend ? dans l'émission C'est Votre Argent présentée par Marc Fiorentino. C'est Votre Argent est à voir ou écouter le vendredi sur BFM Business.

Join HRS Board Member Prashanthan Sanders, MBBS, PhD, FHRS (University of Adelaide) as he discusses this exciting paper, presented at Heart Rhythm 2025. He is joined in the Heart Rhythm Tv Studio in San Diego, California by Louise Segan, MBBS, MPH (Alfred Health), and Takanori Yamaguchi, MD, PhD (Saga University). This discussion took place on-site at Heart Rhythm 2025.   https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)01245-7/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): T. Yamaguchi: Honoraria/Speaking/Consulting: Abbott Japan, Biotronik, Boston Scientific, Abbott Medical, Japan Medtronic, Inc., Daiichi Sankyo, Novartis, Japan Lifeline, Nihon Kohden, Bayer Healthcare Pharmaceuticals Japan, Boehringer Ingelheim L. Segan: Nothing to disclose.

In this episode of the Global Medical Device Podcast, Etienne Nichols and regulatory expert Mike Drues take a critical look at the FDA's Manufacturer and User Facility Device Experience (MAUDE) database. While intended to serve as a vital tool for post-market surveillance, the MAUDE database is fraught with issues—from late reporting and missing data to unclear mission alignment. Mike challenges MedTech professionals to rethink how we engage with the system, exposing how widespread underreporting and data hygiene problems not only weaken safety efforts but also increase legal risk. This eye-opening discussion reveals where the breakdowns are occurring, who's responsible, and what industry and regulators can do to fix it.Key Timestamps[02:30] What is the MAUDE database, and why does it matter?[06:10] The critical difference between reportable and non-reportable adverse events[11:20] Limitations of MAUDE: Why FDA warns against using it for rate comparisons[17:45] Underreporting, late submissions, and missing data: The disturbing stats[25:00] High-profile companies dominating late reporting violations[32:10] Legal consequences: What expert witnesses look for in MAUDE data[38:50] Is it poor systems or lack of regulatory understanding causing failures?[46:00] Recommendations for manufacturers: What responsible reporting looks like[53:20] How FDA could modernize the MAUDE database to better serve patients[1:01:30] Carrots or sticks: Creating incentives vs. penalties for compliance[1:09:00] Final thoughts: The true mission of MAUDE and how to fulfill itStandout Quotes"A report in the MAUDE database is just a historical record. It doesn't say why it happened or who's at fault—just that it happened."— Mike DruesThis quote underscores the limited utility of MAUDE reports and why interpretation requires caution."If you're not a medical device professional without your tools, then you're not really a medical device professional."— Etienne NicholsA poignant reminder that compliance and quality are human-led, not software-enabled by default.Top TakeawaysLate Reporting is Widespread and RiskyNearly 30% of MAUDE reports are filed late, with 10% submitted more than six months past due. This creates legal exposure and potential patient harm.MAUDE Is Misused—Despite FDA WarningsManufacturers commonly use MAUDE for competitive analysis or trend detection, even though the FDA explicitly warns against it.Three Companies Account for Over Half of Late ReportsLarge, well-resourced companies like Medtronic and Becton Dickinson are responsible for a disproportionate share of noncompliance.Electronic Tools Help, but Culture Matters MoreSoftware can support MDR timelines, but organizations still need internal processes and urgency to act responsibly.FDA and Industry Both Need to EvolveSuggestions include AI-driven cross-referencing, tiered reporting urgency, and incentive-based compliance recognition.ReferencesFDA MAUDE Database21 CFR 803.16 – MDR Reporting RequirementsEtienne Nichols on LinkedInMedTech 101: What Is MAUDE and Why Should You Care?Think of the MAUDE database as a public logbook of adverse events involving medical

Ann Latham is the Founder of Uncommon Clarity, a consulting firm helping professionals gain cognitive clarity. As a clarity consultant, she has worked with notable businesses, including Hitachi, Boeing, and Medtronic. Ann is also the author of The Power of Clarity, The Disconnect Principle, The Clarity Papers, and Uncommon Meetings. Her insights have appeared in The New York Times, Bloomberg, and Management Today. In this episode… The word “clarity” is used frequently in business contexts, but what does it mean? For entrepreneurs and leaders, clarity involves identifying your goals and methods for achieving them. How can you gain clarity in all aspects of your professional life? Widely recognized “Clarity Queen,” Ann Latham has discovered the common roadblocks to goal progression, including a lack of specificity and clear communication. She maintains the importance of gathering enough information to make informed decisions about the next steps. This involves identifying specific decisions and action steps and developing detailed plans to execute them. In this episode of the Lead Like a Woman Show, Andrea Heuston sits down with Ann Latham, the Founder of Uncommon Clarity, to discuss how to gain clarity in your professional life. Ann explains how to accelerate results and optimize communication in meetings, the takeaways from her TEDx talk, and insights from her books.

Prashanthan Sanders, MBBS, PhD, FHRS, University of Adelaide is joined by Jenish Shroff, MBBS, MD, Australian National University, and Pugazhendhi Vijayaraman, MD, FHRS, Geisinger Heart Institute, to discuss this first-in-human feasibility study evaluated a novel helix-based leadless pacemaker (LPCSP) designed to achieve left bundle branch area pacing (LBBAP), a capability current LPs lack. The device was temporarily implanted via the internal jugular vein into the interventricular septum in 14 patients, with successful implantation in 10. Electrical performance metrics, including pacing threshold, R-wave amplitude, and impedance, were within acceptable clinical ranges. LBBAP capture was achieved in 5 patients, with no serious device-related adverse events in 85.7% of cases. The study supports the acute safety and feasibility of LPCSP for conduction system pacing.    https://www.hrsonline.org/education/TheLead https://www.heartrhythmjournal.com/article/S1547-5271(25)02378-1/fulltext Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical, Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): P. Vijayaraman: Honoraria/Speaking/Consulting: Biotronik, Boston Scientific, Abbott Medical, Medtronic, Inc. Research (Contracted Grants for PIs and Named Investigators only): Medtronic Fellowship Support: Medtronic J. Shroff: Nothing to disclose.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Minnesota has the highest rate of people working remotely in the Midwest, according to the Minneapolis Federal Reserve. More than a third of workers in the state worked at home at least part time in 2023. But now, five years after the pandemic, the great experiment of remote work is shaking out. More employers are calling workers back to the office. On Monday, tens of thousands of state employees who had been working remotely are required to return to work in person at least 50 percent of the time, complying with a return-to-office order from Gov. Tim Walz. Some private companies, such as 3M and Medtronic, also are dialing back their work-from-home policies and President Donald Trump has sought to end remote work for federal workers.MPR News host Angela Davis discusses what we've learned about remote work — when it works and when it doesn't — and what its future might be. Guests: Chris Farrell is a senior economics contributor for MPR News and Marketplace.  Colleen Flaherty Manchester is a professor and faculty director of the Center for Human Resources and Labor Studies in the Carlson School of Management at the University of Minnesota. She studies flexible work and other benefits and programs offered by employers. Subscribe to the MPR News with Angela Davis podcast on: Apple Podcasts, Spotify or RSS.   Use the audio player above to listen to the full conversation.     

In this episode of Diabetes Dialogue, co-hosts hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss significant developments in diabetes care from May 2025, including Medtronic's restructured business model, Sequel Twiist's technological collaboration with Abbott, and Breakthrough T1D's efforts to advance early detection of type 1 diabetes (T1D) through national screening initiatives. The discussion opens with news of Medtronic's decision to spin off its diabetes division into a standalone entity, currently referred to as “New Diabetes Company.” While the final name is forthcoming, the move is intended to streamline operations and accelerate innovation within the diabetes space. The hosts highlight the company's promising technology pipeline, including the forthcoming 800 series insulin pump with full smartphone control and plans for a tubeless insulin delivery system. Both experts express optimism that the independence may foster greater agility in product development, enhance accessibility, and maintain a focus on user-centered design, including for populations with visual impairments. Next, Isaacs and Bellini examine the announcement of the Sequel Twiist partnership with Abbott to integrate continuous ketone monitoring (CKM) into a hybrid sensor, which is expected to function similarly to the FreeStyle Libre 3. This device, still in development, will provide real-time data on both glucose and ketone levels—a critical advance for people with type 1 diabetes using insulin pumps, who are at elevated risk for diabetic ketoacidosis (DKA). While excited about the potential for earlier DKA detection, Bellini emphasizes the importance of cost-effective implementation and integration with existing pump platforms. The episode concludes with coverage of Breakthrough T1D's advocacy before the US Preventive Services Task Force to support routine screening for T1D autoantibodies. The goal is to identify individuals in early stages of the disease to prevent DKA and misdiagnosis. The hosts note that despite advancements in understanding T1D progression, many patients remain undiagnosed until presenting with DKA or are mistakenly classified as having type 2 diabetes. References: Medtronic plc. Medtronic announces intent to separate Diabetes business. Medtronic News. Published May 21, 2025. Accessed June 2, 2025. https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business Sequel Med Tech. Sequel Med Tech to Integrate twiist Automated Insulin Delivery (AID) System with Abbott's Future Dual Glucose-Ketone Sensor. GlobeNewswire News Room. Published May 22, 2025. Accessed June 2, 2025. https://www.globenewswire.com/news-release/2025/05/22/3086535/0/en/Sequel-Med-Tech-to-Integrate-twiist-Automated-Insulin-Delivery-AID-System-with-Abbott-s-Future-Dual-Glucose-Ketone-Sensor.html Breakthrough T1D. Breakthrough T1D Submits Application to Make Screening for Type 1 Diabetes Part of Recommended Preventive Services in the US - Breakthrough T1D. Breakthrough T1D. Published May 21, 2025. Accessed June 2, 2025. https://www.breakthrought1d.org/for-the-media/press-releases/breakthrough-t1d-submits-application-to-make-screening-for-type-1-diabetes-part-of-recommended-preventive-services-in-the-us/

Scott Korzenowski speaks about his experience working remotely since the pandemic as Medtronic asks their hybrid workers to return to the office four days each week instead of three.

Scott Korzenowski, sitting in for Chad today, mixes in a bunch of Timberwolves and NBA discussion throughout the hour, including a visit with Jon Krawczynski of The Athletic, with a discussion about working from home and a change in hybrid work policy at Medtronic.

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, are joined by Roy Beck, MD, PhD, executive director of the Jaeb Center for Health Research, to discuss the INHALE-3 trial, an adult study evaluating technosphere inhaled insulin (Afrezza) in comparison to standard diabetes therapies, including automated insulin delivery (AID) systems. Beck outlined his center's transition from ophthalmology-focused research to becoming a key player in diabetes trials over the last 25 years, particularly in technology-driven therapies. The conversation explores inhaled insulin's pharmacokinetic profile—its rapid onset and short duration, which more closely mimics physiologic insulin responses than injected rapid-acting analogs. The INHALE-3 trial randomized adults with type 1 diabetes (T1D), including nearly 50% who were on AID systems, to either continue their current regimen or switch to once-daily insulin degludec plus Afrezza for meals and corrections. Surprisingly, Beck highlighted participants willing to suspend AID use to try the inhaled approach, allowing for a head-to-head comparison. The study met its primary non-inferiority endpoint for HbA1c, with outcomes from Afrezza plus basal insulin comparable to those achieved with AID and multiple daily injections. However, Beck emphasized the heterogeneity in response. Approximately 30% of participants switching to Afrezza achieved notably better glycemic control (including greater reductions in HbA1c and less time >250 mg/dL), while a similar proportion performed worse, largely depending on their engagement and dosing frequency. CGM use was required in the study, enabling patients to re-dose Afrezza postprandially as needed, a key factor in those who succeeded. Beck also indicated that overnight glycemic control remained a challenge. While Afrezza performed well during daytime periods, AID systems outperformed it overnight—an expected finding given AID's strength in basal modulation. Weight gain was also lower in the Afrezza group, offering an additional potential advantage. Hosts discussed real-world use cases combining AID with Afrezza, with Beck sharing his son's personal success using Afrezza alongside Tandem Diabetes' Control-IQ in sleep mode, a workaround to prevent algorithmic overlap. He noted future integration could be more seamless with upcoming Bluetooth-enabled Afrezza inhalers or AID systems capable of receiving inhalation data. Safety data showed bronchospasm was rare in the trial, with no confirmed cases attributable to Afrezza. Cough was the most common side effect, generally mild and transient, while active asthma and smoking remained contraindications. Isaacs and Bellini highlighted Afrezza's potential as an underutilized but powerful option in the diabetes toolkit, particularly for patients seeking alternatives to injections or pumps, or looking for greater control over postprandial excursions. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Chapters 00:00:01 Introduction and Background of Dr. Roy Beck 00:02:16 Overview of Inhaled Insulin 00:06:31 INHALE-1 Pediatric Study 00:07:21 INHALE-3 Adult Study 00:11:18 Study Results and Participant Outcomes 00:19:57 Challenges and Future Directions 00:26:44 Side Effects and Safety Concerns 00:31:09 Conclusion and Final Thoughts

#293: Today I'm sitting down for a casual solo episode spilling the tea on how things are going post-rebrand, and sharing my favorite new hack for getting things done when I feel like crashing out.Resources:Follow Marina Girgis on IG to learn more about her retreatsEpisode 225: How Reading Fiction Makes Us Raise Our Standards and Practice Self-Care with Kennedy RyanEpisode 271: How to Rebrand Your Life in 2025Episode 281: Gabrielle Union on Moving Through Creative Blocks, Embracing Vulnerability and No Longer Going 50/50Episode 283: The Business of Rebranding and Owning Your Success with WeezyEpisode 289: Choosing Alignment Over Ambition with Daria BurkeCan't Get Enough by Kennedy RyanOf My Own Making: A Memoir by Daria BurkeSubscribe to my Substack, Balance with LesSponsors:Simply Pop is a new fruit-forward bevy of prebiotic sodas with 6 grams of fiber. Go to cokeurl.com/simplyPOP to find out where you can try it.Nuuly Subscription Clothing Rental is a must-have for switching up your style. Visit nuuly.com and use the code BALANCEDLES to get $28 off your first month.Medtronic is spreading awareness about the importance of talking about women's heart health. Visit alettertomymother.com to learn more.IM8's Daily Ultimate Essentials is my go-to drink for getting all the nutrients I need. Go to IM8health.com/lucky and use code LUCKY for a free welcome kit, five free travel packs, and 10% off your order.Keep in touch:Follow on IG: @shessoluckypod @lesalfredFollow on TikTok: @shessoluckypod @lesalfredVisit our website at balancedblackgirl.comPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A conversation with a Medtronic engineer who's been with the company since the beginning of the Artificial Pancreas project. Lou Lintereur is now Chief Engineer for AID systems at Medtronic.. we talk about the recently approved Simplera Sync Sensor, changes coming to Medtronic pumps, he answers your questions about AI use, patch pumps, and the idea of a pump that needs zero user interaction. Note: this episode was recorded before Medtronic's announcement that they will spin off the Diabetes division. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Send us a textJoin our host, Dr. Byron Stephens, as he speaks with Dr. Michael Kelly and Dr. Steven Glassman, two of the authors of Scoliosis Research Society–funded research recently published in the Journal of American Medical Association -- Surgery. Congratulations to all the authors on this outstanding achievement!The study, Long-Term Outcomes of Operative Versus Nonoperative Treatment for Adult Symptomatic Lumbar Scoliosis (ASLS): Durability of Treatment Effects and Impact of Related Serious Adverse Events Through 8-Year Follow-Up, was published in the Journal on April 2, 2025.To bring the study to its full 8-year follow up allowing for the JAMA publication, funding was provided by the SRS and several of the SRS industry partners and the International Spine Study Group . The SRS community and the study investigators appreciate the additional investments provided above and beyond their support of SRS, made by Globus Medical, K2M/Stryker Spine, Medtronic, NuVasive, and Zimmer Biomet.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

S&P Futures are trading lower this morning. There are news reports indicating that Isreal is preparing to launch a strike on Iran. In March, President Trump gave Iran a 60-day deadline to reach a deal, that deadline has passed. House Republicans appear close to passing their reconciliation bill, The Senate will likely make changes to the bill. If the bill passes in the House and Senate, it will likely be a negative for markets as it will increase the deficit. Yesterday, President Trump unveiled a missile defense plan, LHX shares are higher. Medtronic plans to separate its diabetes business into a stand-alone company. Take Two announced a $1 Billion stock offering. KEYS, BIDU, & LOW are higher after earning announcements. After the bell today SNOW, ZM and URBN are set to report. On Thursday morning ADI, BJ & RL will repor

US House Speaker Johnson said a Thursday tax bill floor vote is still realistic.China's Commerce Ministry said US measures on China's advanced chips are typical of unilateral bullying and protectionism.Europe opened mostly lower but now trade mixed, US equity futures are in the red.USD remains out of love, GBP digests hot CPI data, EUR/USD back above 1.13.Bearish bias in play, Gilts lag after hot CPI, USTs await fiscal updates.Energy and gold boosted by reports Israel is preparing a possible strike on Iranian nuclear facilities.Looking ahead, G7 Central Bank and Finance Ministers Meeting, Speakers including ECB's Lagarde, Lane, Nagel & Cipollone, Fed's Barkin & Bowman, Supply from the US, Earnings from Snowflake, Zoom, Target, TJX, VF Corp & Medtronic.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Celso Otero, gestor de Renta 4 Gestora, repasa la cotización de Target, Lowes, Medtronic y Palo Alto

Die Reaktion auf die meisten Quartalszahlen fallen vor dem Opening der Wall Street negativ aus. Neben Palo Alto Networks, stehen die Aktien von Target, TJX, der VF Corp. und Medtronic teils stärker unter Druck. Die Aktien des Baumarkt-Riesen Lowe's tendieren nach den Ergebnissen hingegen freundlich. Der Dow Jones wird vor allem durch die Aktien von UnitedHealth belastet. Neben einer Abstufung durch die HSBC, mit einem Kursziel von nur noch $270 Dollar, berichtet The Guardian über den zunehmenden Verdacht von Betrug. Dass die Inflation in Großbritannien die Ziele übertroffen hat, treibt außerdem auch die Renditen der US-Staatsanleihen leicht nach oben. CNN berichtet zudem, dass laut Informationen des US-Geheimdienstes, Israel einen Angriff auf Irans Atomanlagen in Erwägung zieht. Ein Podcast - featured by Handelsblatt. +++Erhalte einen exklusiven 15% Rabatt auf Saily eSIM Datentarife! Lade die Saily-App herunter und benutze den Code wallstreet beim Bezahlen: https://saily.com/wallstreet +++ +++EXKLUSIVER NordVPN Deal ➼ https://nordvpn.com/Wallstreet Jetzt risikofrei testen mit einer 30-Tage-Geld-zurück-Garantie!+++ +++ Alle Rabattcodes und Infos zu unseren Werbepartnern findet ihr hier: https://linktr.ee/wallstreet_podcast +++ Der Podcast wird vermarktet durch die Ad Alliance. Die allgemeinen Datenschutzrichtlinien der Ad Alliance finden Sie unter https://datenschutz.ad-alliance.de/podcast.html Die Ad Alliance verarbeitet im Zusammenhang mit dem Angebot die Podcasts-Daten. Wenn Sie der automatischen Übermittlung der Daten widersprechen wollen, klicken Sie hier: https://datenschutz.ad-alliance.de/podcast.html

Die Reaktion auf die meisten Quartalszahlen fallen vor dem Opening der Wall Street negativ aus. Neben Palo Alto Networks, stehen die Aktien von Target, TJX, der VF Corp. und Medtronic teils stärker unter Druck. Die Aktien des Baumarkt-Riesen Lowe's tendieren nach den Ergebnissen hingegen freundlich. Der Dow Jones wird vor allem durch die Aktien von UnitedHealth belastet. Neben einer Abstufung durch die HSBC, mit einem Kursziel von nur noch $270 Dollar, berichtet The Guardian über den zunehmenden Verdacht von Betrug. Dass die Inflation in Großbritannien die Ziele übertroffen hat, treibt außerdem auch die Renditen der US-Staatsanleihen leicht nach oben. CNN berichtet zudem, dass laut Informationen des US-Geheimdienstes, Israel einen Angriff auf Irans Atomanlagen in Erwägung zieht. Abonniere den Podcast, um keine Folge zu verpassen! ____ Folge uns, um auf dem Laufenden zu bleiben: • X: http://fal.cn/SQtwitter • LinkedIn: http://fal.cn/SQlinkedin • Instagram: http://fal.cn/SQInstagram

Today, we're excited to feature Michelle Davey, CEO of Wheel. Wheel is redefining virtual care by connecting clinicians to telehealth opportunities and equipping healthcare organizations with scalable, tech-enabled solutions. Under Michelle's leadership, the company has become a leading platform expanding access to care nationwide. Before Wheel, Michelle brought together experience from Google, Favor Delivery, and Medtronic—insight that now helps shape her vision for the future of care delivery.In this episode, we dive into how Wheel is powering virtual care infrastructure for enterprise healthcare, the strategic thinking behind acquiring GoodRx's virtual care platform, how Michelle sees the future of telehealth evolving across consumer and pharma markets, and what founders should consider when navigating M&A in digital health.

In this episode, I sit down with Shay Domangue, PA-C, whose career path took a bold and inspiring turn — from hospitalist PA/ internal medicine to building her own social media business in elder care to transitioning to marketing development in the pharmaceutical device industry. She's now the Gulf Coast Field Market Development Specialist in the Renal Denervation business unit for Medtronic and is also raising two little humans (with her husband's help).Shay shares what it was like to reach a breaking point in clinical medicine and how listening to that inner voice led her to explore something new. She didn't just walk away — she walked toward a more aligned, values-based life and career.We talk about the early days of entrepreneurship, the emotional and logistical challenges of building something from scratch, and the surprising role that networking played in her transition into the pharmaceutical industry.Shay opens up about redefining success, protecting her energy, and how work-life balance has become a non-negotiable in her new chapter. She also drops some hard-earned wisdom for clinicians who are feeling stuck or wondering what else is out there — especially if you've ever thought, “I can't do this for 20 more years.”This conversation is for you if you're craving purpose, dreaming of flexibility, or just want to hear from someone who's made a major pivot and lived to tell the tale.CONNECT WITH SHAY:Linkedin.com/in/shaydomangueShay's polypharmacy info on TikTok: @elder.care.hubHOPE'S BOOK:⁠⁠Healing Clinician Burnout, How to Revive Your Life and Career ⁠⁠(available in ebook and paperback)CONNECT AND SIGN UP FOR COACHING:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hope's Website: www.coachhopecook.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hope's IG @coachhopecook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hope's FB @hopeallencook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hope's LinkedIn: hope-cook-56041283/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Hope's YouTube @coachhopecook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: hope.cook@gmail.comLove y'all, and remember: There's always hope!

In episode 2 of Launch Point, Jeremy is joined by Orlando Gafford, an expert in Organizational Change Management who's helped companies like Medtronic, Cargill and Grainger successfully navigate transformation. Jeremy and Orlando discuss how to lead through change, empower teams and build lasting adoption -- especially during technology and process shifts.

Medtronic, Inc, etc. v. CIR

Want To Learn How To Grow Your Territory?? If so → https://www.newtomedicaldevicesales.com/podcastFrom filing for bankruptcy to working with the top medical device companies, Roxy Tirado shares her full journey. Topics include grit and perseverance, what it's really like being a female in medical device sales, landing multiple job offers in six weeks, surviving and thriving at Medtronic and Intuitive, the pressure of big-name companies, building confidence, preparing like a pro, investing in mentorship, and staying grounded in gratitude and humility.Key Takeaways:Don't wait for rock bottom. If you're feeling stuck or beat down in your current role, don't wait for a breaking point—make the move now.You don't need sales experience. Roxy broke into top companies like Medtronic with zero B2B sales experience. Hard work and coachability mattered more.Ask for help. Utilize mentors and community. Roxy leaned on others when she doubted herself, and it made all the difference.Be human first, sales rep second. Build relationships with honesty and authenticity. People buy from reps they trust, not robots with brochures.Play the long game. It's not about a quick sale—it's about becoming someone your clients can count on for the long haul.00:00:00 - Start00:02:04 - Who Is Roxy Tirado00:08:00 - What Was Your Experience, First 6 Months With Medtronic00:16:11 - Finding Motivation While Being Told You Will Fail Every Day00:21:09 - Accepting Failure To Succeed00:26:44 - Keep Relationships When You Move On00:39:13 - Changing Companies00:46:09 - Reflecting On From Being Bankrupt To Successful00:55:58 - Biggest Takeaways From The Last 3 Years In My Career01:04:15 - Future Plans

Do you want to get into Medical Device Sales?? If so →  https://www.newtomedicaldevicesales.com/podcastFrom filing for bankruptcy to working with the top medical device companies, Roxy Tirado shares her full journey. Topics include grit and perseverance, what it's really like being a female in medical device sales, landing multiple job offers in six weeks, surviving and thriving at Medtronic and Intuitive, the pressure of big-name companies, building confidence, preparing like a pro, investing in mentorship, and staying grounded in gratitude and humility.Key Takeaways:Don't wait for rock bottom.If you're feeling stuck or beat down in your current role, don't wait for a breaking point—make the move now.You don't need sales experience.Roxy broke into top companies like Medtronic with zero B2B sales experience. Hard work and coachability mattered more.Ask for help.Utilize mentors and community. Roxy leaned on others when she doubted herself, and it made all the difference.Be human first, sales rep second.Build relationships with honesty and authenticity. People buy from reps they trust, not robots with brochures.Play the long game.It's not about a quick sale—it's about becoming someone your clients can count on for the long haul.00:00:00 - Start00:02:04 - Who Is Roxy Tirado00:08:01 - What Was Your Experience, First 6 Months With Medtronic00:16:11 - Finding Motivation While Being Told You Will Fail Every Day00:21:09 - Accepting Failure To Succeed00:26:44 - Keep Relationships When You Move On00:39:13 - Changing Companies00:46:09 - Reflecting On From Being Bankrupt To Successful00:55:58 - Biggest Takeaways From The Last 3 Years In My Career01:04:15 - Future Plans

With us today is award winning television personality Star Jones, who is a longtime Women's Heart Health Advocate. She is here to discuss her journey as a survivor of heart disease and the launch of Medtronic's Letter to My Mother Campaign, which encourages women to take the pledge to talk to their mother or the women in their life about heart health.   Heart disease has been the leading cause of death among women in the U.S. for more than a century and impacts more than 60 million women today. For women of color, these rates are even higher, with 59% of Black women and 43% of Hispanic women experiencing some kind of heart disease.    One-third of women (30%) have not talked with a healthcare provider about their heart health and 56% of women report having never discussed heart health with their mother or other women in their family.   Head over to  ALetterToMyMother.com  and get involved. You could be saving a life. #hearthealth #cardiovascularhealth #womenshealth #womenshearthealth #africanamericanwomen #blackwomen #hispanicwomen #healtlh #medicine #mothersday 

With us today is award winning television personality Star Jones, who is a longtime Women's Heart Health Advocate. She is here to discuss her journey as a survivor of heart disease and the launch of Medtronic's Letter to My Mother Campaign, which encourages women to take the pledge to talk to their mother or the women in their life about heart health.   Heart disease has been the leading cause of death among women in the U.S. for more than a century and impacts more than 60 million women today. For women of color, these rates are even higher, with 59% of Black women and 43% of Hispanic women experiencing some kind of heart disease.    One-third of women (30%) have not talked with a healthcare provider about their heart health and 56% of women report having never discussed heart health with their mother or other women in their family.   Head over to  ALetterToMyMother.com  and get involved. You could be saving a life. #hearthealth #cardiovascularhealth #womenshealth #womenshearthealth #africanamericanwomen #blackwomen #hispanicwomen #healtlh #medicine #mothersday 

Terresa Zimmerman is an entrepreneur, author, advisor, and mentor to business owners. Terresa traveled the world for decades working on business and brand strategy challenges with the world's largest organizations, cross-industry, rooted in B2B, including Fiserv, QUALCOMM, NVIDIA, Brocade, Gerdau, Teck, Medtronic, and more. We can only guess how that led her to become the only female founder of a men's underwear brand, Wood Underwear®. With Wood, she quickly discovered her love for Main Street and all the small businesses that fuel our communities and neighborhoods. She is a 3X award-winning author of the best-selling Oh, Lords! She is an investor and co-founder of an enterprise software company and has been recognized for her advocacy of women founders and aspiring entrepreneurs.Terresa is forever training for another big run and trying to improve her golf game. She and husband, David, live in North Carolina, with Aussies, Whizkey, and Tequila. You can find Terresa on LinkedIn.Connect with Terresa here:https://www.linkedin.com/in/terresachristensonzimmerman/www.woodunderwearwoodunderwear.com and mainstreetmatters.coClick below to download our free template for 3 high-impact posts for LinkedIn:https://www.thetimetogrow.com/ecsposttemplates

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com As care delivery rapidly shifts beyond hospital walls, Medtronic is redefining patient monitoring and safety. In this episode, Blake Tatum, Vice President of U.S. Sales, Marketing, and Global Training for Medtronic Acute Care and Monitoring, discussed how the division supports over 115 million U.S. patients annually with technologies for blood oxygenation, airway management, and patient monitoring. As healthcare shifts toward ambulatory surgery centers (ASCs) and hospital-to-home care, Medtronic is investing in adapting its acute care solutions to these evolving settings. Their focus is on improving patient safety, reducing complications, and increasing efficiency through technologies like BIS anesthesia monitoring and McGrath video laryngoscopes. What sets Medtronic apart is its ability to integrate seamlessly with existing systems, combined with a dedicated ASC support team and access to Medtronic's broader portfolio. The ultimate goal is to deliver clinically proven, scalable solutions that enhance outcomes while meeting new care and reimbursement models. Tune in to learn how Medtronic Acute Care and Monitoring is adapting to support ambulatory surgery centers and hospital-to-home care with innovative, scalable solutions! Resources: Connect with and follow Blake Tatum on LinkedIn. Follow Medtronic on LinkedIn and explore their website. Check out the Medtronic Acute Care and Monitoring website. Check out their Portfolio Brochure here. Listen to Blake Tatum's previous episode on the Outcomes Rocket here. 

Your annual health checkup is a good start. But it's not enough.You're in your 40s. Your doctor says you're fine. Your weight looks fine.But your energy is low. Your sleep is off. Something just feels… off.Amanda Lim sees this every day.She's a Harvard-certified coach and co-founder of Singapore's first Metabolic Clinic,  advising companies like Google, PayPal, and Medtronic.Her message?You can look lean and healthy, and still be metabolically unwell.In Singapore, many people look slim and fit, yet we're facing a diabetes crisis.Most annual checkups don't catch it. They miss key signs like:Skeletal muscle mass (SMI)Visceral fatFasting insulinVO₂ maxIn this episode of How to Live, Amanda and I unpack the real health reset for your 40s — metabolism, muscle, and how to build strength from the inside out.Episode Shownoteshttps://howtolive.life/episode/093-muscle-metabolisim-midlife-reset-with-amanda-limConnect with Amandahttps://www.liftclinic.org/How to Live NewsletterGo deeper with articles every 2-3 weeks. No spam. https://sharadlal.substack.com/ Leave us a messagehttps://howtolive.life/contactAbout Sharad Lalhttps://www.sharadlal.net/Follow usLinkedin: https://www.linkedin.com/in/sharadlal24/Facebook: https://www.facebook.com/PodcastHowtolive/Instagram: https://www.instagram.com/podcasthowtolive/

Colibri Heart Valve LLC v. Medtronic Corevalve, LLC

US equity futures are pointing to a higher open today. European markets are firmer, following notable strength in Asian markets. Global markets influenced by China Commerce Ministry's remark that Beijing is evaluating the US offer on trade negotiations, which signals China's openness to discussions. The softened tone now is being seen as a latest de-escalation signal following recent reports that Beijing has quietly exempted certain US-made goods from tariffs. Japan also aims to achieve a trade agreement with the US in June, though the country has suggested that treasury holdings are among cards it may use in talks.Companies mentioned: Viper Energy, GE HealthCare, Johnson & Johnson, Medtronic, JetBlue Airways

Join host Prashanthan Sanders, MBBS, PhD, FHRS, and episode guests Jason G. Andrade, MD, FHRS, and Melanie Gunawardene, MD, as they discuss Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. This discussion was recorded in person at EHRA 2025 in Vienna, Austria. The article under discussion was presented at EHRA 2025 and simultaneously published in the New England Journal of Medicine.   https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2502280   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical   Contributor Disclosure(s): M. Gunawrdene: Honoraria/Speaking/Consulting: Farapulse, Abbott Medical, Boston Scientific, Medtronic, Biotronik, Luma Vision, Bristol Myers Squibb J. Andrade: Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Inc., Biosense Webster, Inc.

This week, we interviewed Jeremy Laynor, the Senior Vice President of Sales at Providence Medical Technology. We discussed his book The Point Guard Approach. Jeremy offers some insight into what it takes to be a leader at work and at home. Jeremy has a strong track record of success in medical device sales leadership, with specific experience in the spinal implant market. He most recently served as Vice President of Sales at Paradigm Spine, where he was instrumental in growing their commercial effort since 2013. Jeremy held sales leadership positions at Medtronic and previously at Salient Surgical, where he helped the market development of their advanced energy platform to the standard of care for many common orthopedic and spine procedures. He began his healthcare career with Cardinal Health, where he specialized in cultivating national sales teams for new pharmaceutical, biotech, or medical technologies. Jeremy graduated from Slippery Rock University in Pennsylvania, where he played point guard for the men's basketball team. He is a husband and proud father of four children, and the family currently lives in Dallas, Texas.

In this jam-packed episode, Dr. Jeremy Pettus and Dr. Steve Edelman team up with special guest Dr. David Ahn to break down the latest and greatest in diabetes technology for 2025. From extended-wear CGMs to fully automatic hybrid closed-loop pumps and dual-hormonal systems, this episode is your complete guide to what's available now and what's coming soon. Whether you're on MDI, using a pump, or considering a tech upgrade, this conversation will help you navigate the expanding world of devices—and find the right setup for you.Key Topics:Extended-Wear CGMs: The Dexcom G7 now lasts over 15 days—and the Eversense implantable sensor lasts a full year.Over-the-Counter CGMs: Learn about Dexcom Stelo and Abbott Lingo, designed for people without diabetes.New Pump Launches: Including Tandem Mobi, Beta Bionics iLet, Sequel Twist, and Medtronic's MiniMed™ 780G with Simplera Sync sensor.Medtronic Simplera Sync: What to know about its U.S. launch, wear time, and integration with the 780G system.Dual-Hormone Systems: Explore how glucagon is being used alongside insulin to prevent lows and simplify diabetes management.Ketone Monitoring: Continuous ketone sensors are on the horizon, and they could change how we detect and prevent DKA.Improved App Integration: Discover updates in CGM and pump interfaces for iPhone and Android, including Libre 3+ and universal app platforms.Customizing Your Combo: Why matching the right CGM with the right pump (or sticking with MDI) is more doable—and more important—than ever. ★ Support this podcast ★

  If you're feeling like your team is losing to the competition and you can't figure out why, then you are not alone! Your efforts to build a great team might not be working as expected, and instead of improved performance, you might be experiencing disengagement and frustration among your team members. It's time to turn things around and create a winning team culture that drives success. Uncover the surprising twist that takes employee engagement to the next level. You won't believe how a simple shift in perspective can transform teams from average to extraordinary. And the best part? It's a game-changer for any business, regardless of industry. Stay tuned to find out how this unexpected approach leads to exceptional team performance and leaves your competition in awe. You won't want to miss this! Build Great Teams with Collaboration Creating a culture of collaboration within teams fosters innovation and productivity. By encouraging open communication and teamwork, organizations can leverage the diverse skills and perspectives of their members. Collaborative efforts lead to enhanced problem-solving and creativity, driving the team towards success. This week's special guest is Don Yaeger Don Yaeger, a distinguished journalist and accomplished author, boasts an extensive background in sports and business. As the author of 40 books, including 12 New York Times bestsellers, Don's expertise is widely recognized. With a focus on team dynamics and leadership, his insights are particularly valuable for business leaders and managers seeking to optimize team performance and engagement. Don's in-depth research and comprehensive understanding of high-performance principles make him a respected authority in the realm of team building and organizational excellence. His wealth of experience positions him as a leading figure in providing practical strategies and actionable advice for enhancing team effectiveness and driving overall success in the business landscape. This is his story: Don Yaeger, a seasoned journalist and author, shares his journey of discovering the elements that make great teams in business. With a career spanning big newspapers and Sports Illustrated, Don's insatiable appetite for learning led him to write 40 books, with 12 becoming New York Times bestsellers. His relentless pursuit of knowledge didn't stop there; he also hosts the Corporate Competitor podcast, where he delves into the wisdom of successful individuals. Don's immersion in the world of great teams didn't happen overnight. Over a decade, he meticulously studied top-performing sports teams like Nick Saban's Alabama football team and the mid-90s Chicago Bulls, as well as outstanding businesses like Delta Airlines and Chick Fil A. This deep dive culminated in his book "Great Teams," where he identified 16 key differentiators of exceptional teams. Don's journey is a testament to the power of continuous learning and the relentless pursuit of excellence, inspiring leaders and managers to cultivate a culture of growth and engagement within their teams. Great teams are committed to things that average teams aren't. They're committed to things like creating an environment where employees believe that they're locked into each other and that they're beholden to each other, that they're better because of each other. - Don Yaeger In this episode, you will be able to: Uncover the secrets to building great teams that drive business success. Explore the crucial role of culture in achieving outstanding team performance. Implement powerful strategies to boost employee engagement and motivation. Harness the impactful leadership techniques that drive exceptional team performance. Discover invaluable insights from success stories in sports and business.   The key moments in this episode are: 00:00:00 - The Importance of Having a Sense of Purpose 00:07:36 - What Makes Great Teams Great 00:11:49 - Building a Team Others Want to Join 00:13:07 - Overcoming Complacency 00:14:28 - The Power of Coaching and Success Principles 00:16:06 - Success Leaves Clues 00:17:56 - The Role of Team Behavior 00:21:36 - Culture, Behavior, and Habits 00:27:02 - The Power of Purpose 00:29:14 - The Importance of Team Commitment 00:30:43 - Making a Difference in Business 00:34:48 - Employee Engagement and Impact 00:36:35 - What Makes Great Teams Great 00:40:26 - Don Yaeger's All-Time Favorite Movie Timestamped summary of this episode: 00:00:00 - The Importance of Having a Sense of Purpose Don Yaeger emphasizes the importance of not just knowing, but feeling the sense of purpose within a team. He discusses how the best teams believe they are part of something bigger than themselves. 00:07:36 - What Makes Great Teams Great Don Yaeger shares his insights on what makes great teams stand out, highlighting the importance of continuous learning, mentoring culture, and a strong sense of purpose as key factors in achieving greatness. 00:11:49 - Building a Team Others Want to Join Don Yaeger discusses the significance of being the team that others aspire to join. He emphasizes the importance of being the organization that people are working to figure out how to join, rather than the team losing people to competitors. 00:13:07 - Overcoming Complacency Don Yaeger addresses the issue of complacency and its impact on organizations. He discusses how human nature can lead to complacency, and the importance of staying vigilant and continuously improving, even during times of success. 00:14:28 - The Power of Coaching and Success Principles Don Yaeger shares how he coached his son's losing team and emphasized success principles to turn the team's performance around. 00:16:06 - Success Leaves Clues Don Yaeger discusses the importance of studying successful individuals and teams to learn from their experiences and apply those lessons to achieve greatness. 00:17:56 - The Role of Team Behavior Don Yaeger emphasizes the significance of team behavior, communication, and camaraderie in achieving success, rather than solely crediting coaching for a team's victory. 00:21:36 - Culture, Behavior, and Habits Don Yaeger explains how culture shapes behaviors, which in turn form habits leading to sustained excellence, highlighting the importance of intentionally designing a positive culture within organizations. 00:27:02 - The Power of Purpose Don Yaeger shares how a sense of purpose and belonging to something bigger than oneself is crucial for team success, using the example of USA Basketball's transformation under Coach Mike Krzyzewski. 00:29:14 - The Importance of Team Commitment Don Yaeger discusses the importance of basketball players respecting and honoring members of the United States armed forces, emphasizing the responsibility they have as representatives of their country. 00:30:43 - Making a Difference in Business Yaeger shares a story about Medtronic, showing how bringing in families to thank employees for their work makes them realize the impact they have on people's lives, fostering a sense of purpose in their work. 00:34:48 - Employee Engagement and Impact The conversation highlights the significance of employees believing that their work makes a difference and the impact it has on their engagement and satisfaction, ultimately leading to better outcomes for the organization. 00:36:35 - What Makes Great Teams Great Yaeger emphasizes that great teams are committed to creating an environment where employees feel connected and responsible for each other, believing that their work changes lives and treating them differently than other organizations would. 00:40:26 - Don Yaeger's All-Time Favorite Movie Yaeger shares his favorite sports movie, "Hoosiers," emphasizing the idea of coming together to achieve amazing things, reflecting the themes of teamwork and commitment discussed in the episode. Importance of Culture in Teams Culture forms the foundation of a team, shaping behaviors, attitudes, and values. A positive and inclusive culture cultivates trust and unity among team members, fostering a sense of belonging and shared purpose. Leaders play a crucial role in shaping and nurturing a culture that empowers individuals and drives collective success. Effective Employee Engagement Strategies Engaged employees are more productive, motivated, and committed to the organization's goals. Implementing strategies that recognize and value employees' contributions fosters a sense of ownership and loyalty. By soliciting feedback, offering growth opportunities, and promoting a healthy work-life balance, leaders can create a work environment where employees thrive and contribute their best work. The resources mentioned in this episode are: Connect with Don Yaeger on LinkedIn for more insights and inspiration on building great teams. Visit Don Yaeger's website at donyaeger.com to explore his work, books, and speaking engagements. Check out the Corporate Competitor Podcast at corporatecompetitorpodcast.com for valuable leadership and team-building content. Explore Leadfeeder for real-time website visitor tracking and lead engagement to revolutionize your lead generation and sales efforts. Download Fly Message for free to save time and increase productivity with a personal writing assistant and text expander.

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Joost Lumens and Nico Bruining Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1804?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Eoin sits down with Graham to chat about his recent trip with Medtronic to the ATTD conference in Amsterdam.ATTD stands for 'Advanced Technologies & Treatments for Diabetes' and Eoin discusses some of the things he took away from the conference including:His changing attitude towards pumps.Interesting exercises undertaken at the conference.Observations from a restaurant full of T1Ds.As always, be sure to rate, comment, subscribe and share. Your interaction and feedback really helps the podcast. The more Diabetics that we reach, the bigger impact we can make!Questions & Stories for the Podcast?:theinsuleoinpodcast@gmail.comConnect, Learn & Work with Eoin:https://linktr.ee/insuleoin Hosted on Acast. See acast.com/privacy for more information.

In this episode of Work in Progress, Dr. Sally Saba, vice president and global chief inclusion and diversity officer for Medtronic and president of Medtronic Foundation, joins me to discuss the organization's Medtronic Spark initiative, a ten-year global committment to introduce one million students from low-income households into high-paying health tech careers. Technology has transformed the health care sector for the past few decades, from robotics to wearable technology, to telemedicine, and, of course, artificial intelligence. This is creating a huge and growing talent gap in health tech, both in the U.S. and around the world. And the way you do those jobs is also changing. "They say between around 11 million of shortages just within the next four to five years. You add onto that how AI is going to transform and evolve the landscape of education faster than people can keep up," says Dr. Saba. The Medtronic Spark initiative intends to prepare one million workers for those jobs today and in the future. "They say that 65% of students in schools today will work in jobs that don't even exist yet, and 45% of the workforce today will need new reskilling to even be able to keep up with that future." Saba adds. In the podcast, she explains that initiative will focus on students through high school, right before they start looking at their careers. 'We don't want to touch lives, we want to change the trajectory of lives,' Saba says. Medtronic Spark will be a combination of online and hands-on training, with a focus on making it accessible for low-incoming families. It will include three main components: innovation labs for students to tinker with technology, scholarships to help students graduate, and job-ready credential programs in high-demand health care technology roles like clinical mapping and pacemakers. Medtronic employees will be able to get involve by sponsoring students, providing mentorship, and helping designing credentialling programs. Medtronic is in 150 countries and 40% of the initial programing will be in the U.S. Find out more details of the initiative in the podcast, which you can listen to here or wherever you get your podcasts. You can also find our podcasts on the Work in Progress YouTube channel. Episode 360: Dr. Sally Saba, VP Chief Global Inclusion and Diversity Officer, Medtronic; President, Medtronic FoundationHost & Executive Producer: Ramona Schindelheim, Editor-in-Chief, WorkingNationProducer: Larry BuhlTheme Music: Composed by Lee Rosevere and licensed under CC by 4Transcript: Download the transcript for this episode hereWork in Progress Podcast: Catch up on previous episodes here

Join host and Digital Education Chair Prashanthan Sanders, MBBS, PhD, FHRS, as he discusses this article from Nature with guests Anand N Ganesan, MBBS, PhD, and Tina Baykaner, MD, MPH. This trial was also presented as a late-breaking clinical trial at Heart Rhythm 2024.   https://www.hrsonline.org/education/TheLead https://www.nature.com/articles/s41591-025-03517-w   Host Disclosure(s): P. Sanders: Honoraria/Speaking/Consulting: Boston Scientific, Abbott Medical Research: Boston Scientific, Abbott, Medtronic, Becton Dickinson, CathRx, Pacemate, Kalyan Technologies, Ceryx Medical, Biosense Webster, Inc., Hello Alfred, Abbott Medical; Membership on Advisory Committees: Pacemate, Medtronic PLC, Boston Scientific, CathRx, Abbott Medical Contributor Disclosure(s): A. Ganesan: Honoraria/Speaking/Consulting: Biosense Webster, Inc. T. Baykaner: Honoraria/Speaking/Consulting: Medtronic, Pacemate, Volta Medical, iRhythm Technologies; Research: NIH   This episode is worth 0.25 ACE credits. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode99

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

LIVE from Transform 2025 in Las Vegas! Amira Barger is an award-winning Executive Vice President of Communications and Head of DEI Advisory at Edelman, providing senior reputation management and polycultural counsel to clients across the globe. Recently named Woman of the Year by Women Health Care Executives, Top 100 Executives by Involve People, Top CMOs of 2024 by the CMO Alliance, Top 50 Global DEI Professionals by OnConferences, Top 100 People Leaders by Mogul, Fearlessly Authentic Leader by Leaderology, and 30 under 40 in Healthcare Innovation by Business Insider – Amira is a scholar, practitioner and thought leader who brings more than 20 years of experience in strategic communications that reach stakeholders, mobilize the community and inspire action. Amira has global experience in pharma/healthcare communications, corporate branding, web and social media, M&A experience, media relations, team management, sustainability/social impact, reputation management, and DEI. Throughout her career, Amira has utilized these competency areas for clients such as: CVS Health, Eli Lilly, Walgreens, Hologic, Genentech, Pfizer, GSK/Haleon, BMS, Zoetis, Alkermes, Regeneron, Amgen, Medtronic, Children's Miracle Network, Kaiser Permanente, First 5 Los Angeles, Covered California, Centers for Disease Control and Prevention, FEMA, and California Community Colleges. Adam and Amira discuss: - How does “niceness” in workplace culture hold back real DEI progress, and what should leaders do instead? - Challenging Workplace Norms to Advance DEI and Justice - Empowering Women in Leadership - Valuing the Whole Human - "How can leaders move beyond surface-level well-being initiatives to truly create workplaces that honor employees as whole humans, not just workers? Connect with Amira: https://www.linkedin.com/in/amirabarger/ Live from Transform 2025, we're bringing you an exclusive podcast series packed with insights from some of the brightest minds in hiring, talent strategy, and workforce transformation! In this series, we've got incredible guests from Okta, Tubi, Edelman, Greenhouse, Findem, and more, sharing how top organizations are rethinking hiring, culture, and talent acquisition in today's fast-changing world. Greenhouse combines a structured, data-driven hiring approach with AI-embedded workflows that empower recruiters to focus on strategic, high-impact work. From sourcing top talent to personalizing the candidate experience, Greenhouse streamlines and optimizes the entire hiring process. This ensures that every hire is the right hire—eliminating bias, creating fairness, and helping teams make smarter, faster decisions. Over 7,500 companies, including HubSpot, Duolingo, and J.D. Power, trust Greenhouse to build better teams and turn talent into a strategic advantage. Want to learn how today's top companies are winning the talent game? Tune in now and visit Greenhouse.com to transform the way you hire. Thanks for listening. Please follow us on Instagram @NHPTalent and X @AdamJPosner. Visit www.thePOZcast.com for all episodes

In this special crossover episode with Physicianary, previous Gut Talk guest, Austin Chiang, MD, and Physicianary host, Hansa Bhargava, MD, discuss the influence of social media in medicine and how AI continues to change the health care landscape. •    Intro 0:30 •    Austin Chiang, MD, MPH 0:36 •    Tell us about your journey. 1:02 •    How did you get involved with being a social media officer at your institution? 3:58 •    Where do you think doctors should see themselves in the future of social media in medicine? 6:49 •    What are the ways in which you see AI tech making a difference? 9:12 •    Do you agree that it is helpful for doctors to be involved with product development and integration on an industry level? 12:14 •    Can you give us some insight on the process of putting through new CPT codes as a company?  14:41 •    Tell me more about your book, Gut: An Owner's Guide (The Body Literacy Library). What motivated you to write this book, and what do you think people will get out of it? 18:35 •    If you were the “king of health care”, what would you work on first? What is the most important aspect of health car that you think needs fixing? 21:23 •    What's your favorite food? 25:24 •    How to reach Chiang. 26:01 •    Thanks 26:20 Austin Chiang, MD, MPH, is the first chief medical officer for the endoscopy business of Medtronic, the global leader in health technology. He is also currently an assistant professor of medicine at an academic teaching hospital in Philadelphia, PA, and serves as the director of the Endoscopic Weight Loss Program. Listen to Gut Talk's very first episode with Dr. Chiang from 2019, Social Media in Medicine. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Follow Dr. Bhargava on X @hansabhargavaMD and on Instagram @doctorhansaMD. Follow Dr. Chiang everywhere on social media @AustinChiangMD. Disclosures: Bhargava reports no relevant financial disclosures. Chiang reports he is the chief medical officer for Medtronic Endoscopy.

Let's talk liver ablations. This week's episode of the BackTable Podcast provides a thorough review of modern microwave ablation methods, tools, and tech, featuring Dr. Asad Baig (interventional radiologist at Columbia University) and host Dr. Michael Barraza. --- This podcast is supported by an educational grant from Medtronic . --- SYNPOSIS Dr. Baig shares practical advice on how to become a key contributor at your tumor board and how to position your skillset as an interventional radiologist. He talks through his microwave ablation procedure technique, highlighting the role of ablation zone visualization software. The doctors go on to discuss a variety of ablation approaches, needle placement, intra- and post-operative imaging, and tips for dealing with challenging tumor locations. The episode concludes with Dr. Baig summarizing best practices for ensuring safe and effective ablations, and underscoring the importance of solid patient-physician communication throughout care. --- TIMESTAMPS 00:00 - Introduction 08:28 - Microwave Ablation Techniques 12:54 - Collaborative Approach in Tumor Boards 23:30 - Combined Ablation Cases and Techniques 36:12 - Challenging Liver Ablations 45:56 - Tips for Safe and Effective Ablations 50:07 - Balancing Biopsy and Ablation 01:00:34 - Conclusion --- RESOURCES The Emprint™ Ablation System with Thermosphere™ Technology: One of the Newer Next-Generation Microwave Ablation Technologies: https://pmc.ncbi.nlm.nih.gov/articles/PMC4640908/ Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria: https://pubmed.ncbi.nlm.nih.gov/24628534/ Percutaneous microwave ablation of hepatic lesions near the heart: https://pubmed.ncbi.nlm.nih.gov/34805581/ Microwave Ablation of Hepatic Tumors Abutting the Diaphragm Is Safe and Effective: https://ajronline.org/doi/10.2214/AJR.14.12879

Visit thedigitalslicepodcast.com for complete show notes of every podcast episode. Join Brad Friedman and Saul Marquez as they discuss the ins and outs of marketing strategies and tactics for practices, vendors and healthcare systems.  Saul Marquez is a prominent figure in healthcare digital marketing, serving as the founder and CEO of Outcomes Rocket a global digital marketing agency serving healthcare clients exclusively. With over twenty years of experience in sales and marketing within the healthcare sector, Saul's journey began in sales and leadership roles at major players like Stryker, NuVasive, and Medtronic. Recognizing significant gaps that companies were faced with in strategy, digital marketing, and commercialization during his career, Saul established Outcomes Rocket to address these challenges head-on. The consultancy focuses on helping healthcare brands and businesses scale and thrive in the digital age. The Digital Slice Podcast is brought to you by Magai. Up your AI game at https://friedmansocialmedia.com/magai